Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.

home / news releases / MBIO - Mustang Bio plans to start phase 1 trial of combo therapy for brain cancer

MBIO - Mustang Bio plans to start phase 1 trial of combo therapy for brain cancer

Mustang Bio Inc.
Mustang Bio (NASDAQ:MBIO) said plans to begin a phase 1 trial combining CAR T cells and oncolytic virus to treat recurrent glioblastoma (rGBM), a type of brain cancer. The company said its decision was supported by interim data from two ongoing phase 1 trials evaluating two candidates, MB-108 (C134 oncolytic virus) and MB?101 (City of Hope’s IL13R?2?targeted CAR T cell therapy). MB?101 and MB-108 were well tolerated in patients with recurrent GBM in ongoing phase 1 trials, the company noted in an April 13 press release. Mustang Bio (MBIO) added that preclinical data also support the safety of administering the two therapies sequentially in a regimen designated as MB-109.

For further details see:

Mustang Bio plans to start phase 1 trial of combo therapy for brain cancer
Stock Information
Company Name: Mustang Bio Inc.
Stock Symbol: MBIO
Market: NASDAQ
Website: mustangbio.com
Menu
MBIO MBIO Quote MBIO Short MBIO News MBIO Articles MBIO Message Board
Get MBIO Alerts

News, Short Squeeze, Breakout and More Instantly...